PTC Therapeutics Inc (PTCT) News & EventsPTCTPTC Therapeutics Inc

PTC Therapeutics to Present Sephience Data at 2026 SSIEM Annual Symposium

PTC Therapeutics announced that multiple sephience scientific data presentations will be featured at the 2026 Society for the Study of Inborn Errors of Metabolism Annual Symposium, taking place in Helsinki, Finland, from Aug. 25-28. The presentations include new data from clinical trials and real-world evidence which reinforce the clinically meaningful benefits of Sephience on lowering phenylalanine, significant diet liberalization and sustained metabolic control for the full spectrum of individuals living with phenylketonuria including those with classical PKU. In addition, Sephience studies continue to show a consistent and favorable safety profile. "The SSIEM presentations further demonstrate the broad clinical benefits of Sephience across the full spectrum of individuals living with PKU," said Matthew Klein, M.D., Chief Executive Officer. "In addition, new data to be presented at the PTC symposium show treatment with Sephience led to a large number of responsive participants achieving normalization of blood Phe levels in a rapid timeframe, including those with classical or non-BH4-responsive PKU. These impressive data support the potential benefits Sephience can deliver for individuals affected by PKU."

PTC Therapeutics Plans to Offer $500M Convertible Senior Notes

PTC Therapeutics announced that it intends to offer $500M aggregate principal amount of Convertible Senior Notes due 2031 to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.